#Australia #Breast Cancer #Sydney #Kazia Therapeutics #Paxalisib

Kazia Therapeutics Expands Clinical Trial for HR+/HER2- Breast Cancer

Kazia Therapeutics Limited, a biotech company focused on oncology therapy, has announced an expansion of its clinical trial for the treatment of hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer. This decision comes in light of new preclinical data demonstrating strong clinical activity and safety for their drug candidate, paxalisib, in combating this common breast cancer type, which accounts for approximately 60-70% of diagnoses.

Promising Preclinical Findings

The recent studies indicate that paxalisib, when used in combination with existing standard-of-care therapies, exhibits significant antitumor effectiveness while being well tolerated by patients. Dr. John Friend, CEO of Kazia, emphasized the critical need for better treatment options, as the U.S. anticipates nearly 322,000 new HR+/HER2- breast cancer cases this year alone. The ongoing research suggests that paxalisib may sensitize tumors resistant to current treatments, an encouraging result that the company is eager to explore further in clinical settings.

Kazia plans to incorporate this new data-driven strategy into its ongoing triple-negative breast cancer (TNBC) trial, thereby expanding its scope to include HR+/HER2- advanced breast cancer. Alongside the patent application to protect these promising findings, the modification of the ongoing trial protocol aims to evaluate paxalisib in patients previously treated for this cancer subtype.

Trial Design and Patient Enrollment

This innovative three-arm trial expansion will compare the efficacy of paxalisib in combination with fulvestrant (a hormone therapy) and palbociclib (a CDK4/6 inhibitor) against a standard-of-care group receiving only fulvestrant. With plans to begin enrolling the first patient by the end of 2026, Kazia envisages complete enrollment by late 2027. The primary focus will be on the safety and tolerability of treatments, while secondary outcomes include measuring progression-free survival, overall response rates, and overall survival metrics.

Dr. Sudha Rao, the company’s Chief Scientific Officer, reiterated the distinct approach of paxalisib, particularly in targeting the resistance mechanisms that HR+ breast cancer tumors often develop against conventional therapies. The early data reveal that paxalisib targets a unique epigenetic axis associated with cancer resistance, differentiating it from other therapies currently in use.

The Clinical Landscape for Breast Cancer Treatments

While current treatment regimens tend to rely on sequencing additional lines of therapy once resistance has arisen, Kazia's findings suggest that paxalisib could potentially address these resistance mechanisms earlier in the treatment paradigm. The identification of a novel PI3K/mTOR biomarker within this research may play a critical role in refining patient selection and optimizing treatment pathways, thereby applying principles of precision medicine to HR+ breast cancer.

Future Directions

Kazia is committed to advancing the development of paxalisib and plans to present new data later this year. Their ongoing exploration into the cellular, molecular, and epigenetic characteristics of paxalisib is vital as it seeks to carve a significant niche in the breast cancer treatment landscape. The anticipated progress in clinical trials will also align with the increasing push for innovative solutions to longtime challenges in oncology, particularly for hard-to-treat cancers like HR+/HER2- breast cancer.

As the company gears up for these developments, the medical community eagerly awaits the potential enhancements in patient outcomes resulting from their advancements. Kazia Therapeutics represents a beacon of hope for individuals fighting HR+/HER2- breast cancer and symbolizes the transformative promise that innovative biotechnology can offer in the battle against cancer.

For additional details, please visit Kazia's official sitio or follow their updates on social media.